Skip to main content Accessibility help
×
Home

National Survey of Thai Infectious Disease Physicians on Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: The Role of Infection Control Awareness

  • Aubonphan Buppajarntham (a1), Anucha Apisarnthanarak (a1), Thana Khawcharoenporn (a1), Sasinuch Rutjanawech (a1) and Nalini Singh (a2)...

Abstract

OBJECTIVE

To evaluate the expected and treatment outcomes of Thai infectious disease physicians (IDPs) regarding carbapenem-resistant Acinetobacter baumannii (CRAB) ventilator-associated pneumonia (VAP)

METHODS

From June 1, 2014, to March 1, 2015, survey data regarding the expected and clinical success rates of CRAB VAP treatment were collected from all Thai IDPs. The expected success rate was defined as the expectation of clinical response after CRAB VAP treatment for the given case scenario. Clinical success rate was defined as the overall reported success rate of CRAB VAP treatment based on the clinical practice of each IDP. The expected and clinical success rates were divided into low (<60%), standard (60%–80%), and high (>80%) categories and were then compared with standard clinical response rates archived in the existing literature.

RESULTS

Of 183 total Thai IDPs, 111 (60%) were enrolled in this study. The median expected and clinical success rates were 68% and 58%, respectively. Using multivariate analysis, we determined that working in a hospital that implemented the standard intervention combined with an intensified infection control (IC) intervention for CRAB (adjusted odds ratio [aOR], 3.01; 95% confidence interval [CI], 1.17–7.73; P=.02) was associated with standard and high expected rates (>60%). Being a board-certified IDP (aOR, 5.76; 95% CI, 2.16–15.37; P<.01) and having higher number of ID consultation cases per month (aOR, 4.84; 95% CI, 1.98–11.80; P<.01) were associated with standard and high clinical success rates (>60%). We identified a significant correlation between expected and clinical success rates (r=0.58; P<.001).

CONCLUSIONS

Awareness of IC among IDPs can improve physicians’ expected and clinical success rates for CRAB VAP treatment, and treatment experience impacts overall treatment success.

Infect. Control Hosp. Epidemiol. 2015;37(1):61–69

Copyright

Corresponding author

Address correspondence to Anucha Apisarnthanarak, MD, Division of Infectious Diseases, Faculty of Medicine, Thammasat University, Pathumthani, Thailand, 10120 (anapisarn@yahoo.com).

References

Hide All
1. Higgins, PG, Dammhayn, C, Hackel, M, Seifert, H. Global spread of carbapenem-resistant Acinetobacter baumannii . J Antimicrob Chemother 2010;65:233238.
2. Mugnier, PD, Poirel, L, Naas, T, Nordmann, P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii . Emerg Infect Dis 2010;16:3540.
3. Young, LS, Sabel, AL, Price, CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol 2007;28:12471254.
4. Betrosian, AP, Frantzeskaki, F, Xanthaki, A, Douzinas, EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008;56:432436.
5. Chan, JD, Graves, JA, Dellit, TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 2010;25:343348.
6. Gurjar, M, Saigal, S, Baronia, AK, et al. Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: clinical characteristics and outcome. Indian J Crit Care Med 2013;17:129134.
7. Chang, HC, Chen, YC, Lin, MC, et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. J Formos Med Assoc 2011;110:564571.
8. Vahdani, P, Yaghoubi, T, Aminzadeh, Z. Hospital acquired antibiotic-resistant Acinetobacter baumannii infections in a 400-bed hospital in Tehran, Iran. Int J Prev Med 2011;2:127130.
9. Gaynes, R, Edwards, JR, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005;41:848854.
10. Kanafani, ZA, Kara, L, Hayek, S, Kanj, SS. Ventilator-associated pneumonia at a tertiary-care center in a developing country: incidence, microbiology, and susceptibility patterns of isolated microorganisms. Infect Control Hosp Epidemiol 2003;24:864869.
11. Paul, M, Weinberger, M, Siegman-Igra, Y, et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals, 1997–2002. J Hosp Infect 2005;60:256260.
12. Danchaivijitr, S, Judaeng, T, Sripalakij, S, Naksawas, K, Plipat, T. Prevalence of nosocomial infection in Thailand, 2006. J Med Assoc Thai 2007;90:15241529.
13. Chawla, R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infect Control 2008;36:S93S100.
14. Werarak, P, Kiratisin, P, Thamlikitkul, V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. J Med Assoc Thai 2010;93:S126S138.
15. NARST: National Antimicrobial Resistance Surveillance Center, Thailand, Web site. http://narst.dmsc.moph.go.th/. Published 2014. Accessed Febuary 2, 2015.
16. Bassetti, M, Righi, E, Esposito, S, Petrosillo, N, Nicolini, L. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol 2008;3:649660.
17. Tripodi, MF, Durante-Mangoni, E, Fortunato, R, Utili, R, Zarrilli, R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007;30:537540.
18. Rodriguez, CH, De Ambrosio, A, Bajuk, M, et al. In vitro antimicrobial activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 2010;4:164167.
19. Tan, TY, Lim, TP, Lee, WH, Sasikala, S, Hsu, LY, Kwa, AL. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 2011;55:436438.
20. Falagas, ME, Kasiakou, SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:13331341.
21. Lu, Q, Girardi, C, Zhang, M, et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa . Intensive Care Med 2010;36:11471155.
22. Imberti, R, Cusato, M, Villani, P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010;138:13331339.
23. Kalin, G, Alp, E, Akin, A, Coskun, R, Doganay, M. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 2014;42:3742.
24. Management of multidrug-resistant organism in healthcare settings. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/hicpac/mdro/mdro_0.html. Published 2006. Accessed Febuary 2, 2015.
25. Magiorakos, AP, Srinivasan, A, Carey, RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268281.
26. Kaye, KS, Harris, AD, McDonald, JR, Strausbaugh, LJ, Perencevich, E, Infectious Diseases Society of America Emerging Infections N. Measuring acceptable treatment failure rates for community-acquired pneumonia: potential for reducing duration of treatment and antimicrobial resistance. Infect Control Hospi Epidemiol 2008;29:137142.
27. Perencevich, EN, Harris, AD, Kaye, KS, et al. Physicians acceptable treatment failure rates in antibiotic therapy for coagulase-negative staphylococcal catheter-associated bacteremia: implications for reducing treatment duration. Clin Infect Dis 2005;41:17341741.
28. Perencevich, EN, Kaye, KS, Strausbaugh, LJ, Fisman, DN, Harris, AD, Infectious Diseases Society of America Emerging Infections N. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: a survey of infectious diseases consultants. Clin Infect Dis 2004;38:476482.
29. Lister, PD, Wolter, DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa . Clin Infect Dis 2005;40:S105S114.
30. Gribble, MJ, Chow, AW, Naiman, SC, et al. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 1983;24:388393.
31. Fish, DN, Piscitelli, SC, Danziger, LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995;15:279291.
32. Hilf, M, Yu, VL, Sharp, J, Zuravleff, JJ, Korvick, JA, Muder, RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540546.
33. Hirsch, EB, Tam, VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;65:11191125.
34. Bodey, GP, Jadeja, L, Elting, L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985;145:16211629.
35. Daikos, GL, Tsaousi, S, Tzouvelekis, LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58:23222328.
36. Raineri, E, Pan, A, Mondello, P, Acquarlo, A, Candiani, A, Crema, L. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am J Infect Control 2008;36:283290.
37. Jenkins, TC, Price, CS, Sabel, AL, Mehler, PS, Burman, WJ. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:10001008.
38. Rieg, S, Peyerl-Hoffmann, G, de With, K, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation—a study of 521 patients in Germany. J Infect 2009;59:232239.
39. Doern, GV, Vautour, R, Gaudet, M, Levy, B. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 1994;32:17571762.
40. Elhanan, G, Sarhat, M, Raz, R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection. J Infect 1997;35:283288.
41. Gomez, J, Conde Cavero, SJ, Hernandez Cardona, JL, et al. The influence of the opinion of an infectious disease consultant on the appropriateness of antibiotic treatment in a general hospital. J Antimicrob Chemother 1996;38:309314.
42. Byl, B, Clevenbergh, P, Jacobs, F, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999;29:6066.
43. Apisarnthanarak, A, Danchaivijitr, S, Bailey, TC, Fraser, VJ. Inappropriate antibiotic use in a tertiary care center in Thailand: an incidence study and review of experience in Thailand. Infect Control Hosp Epidemiol 2006;27:416420.
44. Apisarnthanarak, A, Bhooanusas, N, Yaprasert, A, Mundy, LM. Carbapenem de-escalation therapy in a resource-limited setting. Infect Control Hosp Epidemiol 2013;34:13101313.
45. Apisarnthanarak, A, Khawcharoenporn, T, Mundy, LM. Practices to prevent multidrug-resistant Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus in Thailand: a national survey. Am J Infect Control 2013;41:416421.
46. Petrak, RM, Sexton, DJ, Butera, ML, et al. The value of an infectious diseases specialist. Clin Infect Dis 2003;36:10131017.
Type Description Title
WORD
Supplementary materials

Buppajarntham supplementary material
Appendix

 Word (42 KB)
42 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed